2. UroToday Home
  3. Conference Highlights
  4. 2019 International Bladder Cancer Network

IBCN 2019: An Update to the UROMOL Non-Muscle Invasive Bladder Cancer Classification

Aarhus, Denmark (UroToday.com) Sia Lindskrog and Frederik Prip presented an update to the UROMOL Non-Muscle Invasive Bladder Cancer (NMIBC) classification. Previously, three major molecular subtypes were identified. With an updated cohort of 537 patients with non-muscle invasive disease, multiplexed immunofluorescence was performed on a subset of these tumors to identify T helper cells, cytotoxic T lymphocytes, regulatory T cells, macrophages, B cells, and MHC expressing carcinoma cells.

Four major classes are now identified: class 1, class 2a (new) and class 2b (new), and class 3. Class 2a tumors were described as showing the least favorable prognosis while class 2b tumors were of a highly immune-infiltrated subtype. Better survival was observed in patients with this latter subtype. Although additional external validation is required, Dr. Lindskrog and Prip report that this updated classification may provide an improved framework for future trials in the NMIBC space.

IBCN2019_UROMOL_NMIBC_classification.png

Abstract take-home message:
  •  An update to the UROMOL study identified four major subtypes for NMIBC: class 1, class 2a and 2b, and class 3. Class 2a tumors were described as showing the least favorable prognosis while class 2b tumors were of a highly immune-infiltrated subtype.


Presented by: Sia Viborg Lindskrog, BS, and Frederik Prip, Aarhus University Hospital, Aarhus, Denmark

Written by Dr. Vikram M. Narayan (@VikramNarayan), Urologic Oncology Fellow with Ashish M. Kamat, MD (@UroDocAsh), Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX at the 17th meeting of the International Bladder Cancer Network, (IBCN, #IBCN2019) October 3rd – 5th, 2019 in Aarhus, Denmark.